Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi-Aventis To Assume Development Of Phase III Anticancer Agent S-1

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi will pay Taiho Pharmaceutical up to $360 mil. for S-1, which combines two enzyme inhibitors with the 5-FU prodrug tegafur.

You may also be interested in...



Sanofi-Aventis Gastric Cancer Drug Shows Significant Reduction In Risk Of Death

Company plans to file the oral fluorouracil candidate S-1 in 2009 or 2010.

Sanofi-Aventis Gastric Cancer Drug Shows Significant Reduction In Risk Of Death

Company plans to file the oral fluorouracil candidate S-1 in 2009 or 2010.

Merck KGaA Acquires Rights For Colorectal Cancer Therapy UFT From Taiho

Germany-based Merck says it has not decided whether it will seek FDA approval for the uracil/tegafur combination; FDA deemed UFT “not approvable” for advanced colorectal cancer in 2001, when Bristol held rights to the agent.

Topics

UsernamePublicRestriction

Register

SC143429

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel